Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia

被引：54

作者：

Anensen, N. ^{[9
]}

Hjelle, S. M. ^{[9
]}

Van Belle, W. ^{[2
]}

Haaland, I. ^{[9
]}

Silden, E. ^{[9
]}

Bourdon, J-C ^{[3
]}

Hovland, R. ^{[4
]}

Tasken, K. ^{[5
,6
]}

Knappskog, S. ^{[7
,8
]}

Lonning, P. E. ^{[7
,8
]}

Bruserud, O. ^{[9
]}

Gjertsen, B. T. ^{[1
,9
]}

机构：

[1] Univ Bergen, Haukeland Univ Hosp, Hematol Sect, Dept Internal Med,Inst Med, N-5021 Bergen, Norway

[2] Norut IT, Tromso, Norway

[3] Univ Dundee, Sch Med, Dept Surg & Mol Oncol, Inserm European Associated Lab Inserm, Dundee, Scotland

[4] Haukeland Hosp, Ctr Med Genet & Mol Med, N-5021 Bergen, Norway

[5] Univ Oslo, Biotechnol Ctr, Oslo, Norway

[6] Univ Oslo, Ctr Mol Med Norway, Nord EMBL Partnership, Oslo, Norway

[7] Univ Bergen, Sect Oncol, Inst Med, N-5021 Bergen, Norway

[8] Haukeland Hosp, Dept Oncol, N-5021 Bergen, Norway

[9] Univ Bergen, Inst Med, Hematol Sect, N-5021 Bergen, Norway

来源：

ONCOGENE | 2012年 / 31卷 / 12期

关键词：

p53 protein isoform; p53; beta; gamma; acute myeloid leukemia/NPM1/FLT3-ITD; ACUTE MYELOGENOUS LEUKEMIA; AML; 10; FUNCTIONAL-CHARACTERIZATION; KINASE-ACTIVITY; CHEMOTHERAPY; GENE; NUCLEOPHOSMIN; ACTIVATION; PROGNOSIS; TRANSPLANTATION;

D O I：

10.1038/onc.2011.348

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The wild-type tumor-suppressor gene TP53 encodes several isoforms of the p53 protein. However, while the role of p53 in controlling normal cell cycle progression and tumor suppression is well established, the clinical significance of p53 isoform expression is unknown. A novel bioinformatic analysis of p53 isoform expression in 68 patients with acute myeloid leukemia revealed distinct p53 protein biosignatures correlating with clinical outcome. Furthermore, we show that mutated FLT3, a prognostic marker for short survival in AML, is associated with expression of full-length p53. In contrast, mutated NPM1, a prognostic marker for long-term survival, correlated with p53 isoforms beta and gamma expression. In conclusion, p53 biosignatures contain useful information for cancer evaluation and prognostication. Oncogene (2012) 31, 1533-1545; doi:10.1038/onc.2011.348; published online 22 August 2011

引用

页码：1533 / 1545

页数：13

共 50 条

[21] Frequency of NPM1 Mutations in Pakistani Acute Myeloid Leukemia Patients
Ali, Akbar
Siddique, Muhammad Kamran
Gale, Rosemary E.
Shakoori, Abdul Rauf
PAKISTAN JOURNAL OF ZOOLOGY, 2013, 45 (05) : 1429 - 1436
[22] NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia
Palmisano, Michela
Grafone, Tiziana
Ottaviani, Emanuela
Testoni, Nicoletta
Baccarani, Michele
Martinelli, Giovanni
HAEMATOLOGICA, 2007, 92 (09) : 1268 - 1269
[23] Characterization of NPM1, FLT3, and IDH1 mutations in adult patients with acute myeloid leukemia: a Brazilian cohort study
Cruz, Nathalia Gomide
Tiburcio Ribeiro, Ana Flavia
Firmato Gloria, Ana Beatriz
Abbas, Saman
Assumpcao, Juliana Godoy
Eloi Santos, Silvana Maria
Rezende, Suely Meireles
Xavier, Sandra Guerra
Fagundes, Evandro M.
LEUKEMIA & LYMPHOMA, 2016, 57 (12) : 2901 - 2904
[24] Integrin expression and adhesivity to fibronectin in primary acute myeloid leukemia cells: Impact of NPM1 and FLT3 mutations
Kuzelova, Katerina
Obr, Adam
Markova, Jana
Gasova, Zdenka
EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 105 (05) : 578 - 587
[25] FLT3 and NPM1 Mutations in Myelodysplastic Syndromes Frequency and Potential Value for Predicting Progression to Acute Myeloid Leukemia
Bains, Ashish
Luthra, Rajyalakshmi
Medeiros, L. Jeffrey
Zuo, Zhuang
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2011, 135 (01) : 62 - 69
[26] Pre-B acute lymphoblastic leukemia presenting with NPM1 and FLT3 mutations
Khan, Alesia A.
James, Daniel
Andresen, Vibeke
Atkey, Julie
Bradbury, Rachel
Cargo, Catherine
Dillon, Richard
Gjertsen, Bjorn Tore
Goldstone, Antony R.
Leach, Richard
Lock, Daniel
Narayanan, Mayanka
Russell, Nigel
Verigou, Eleni-Anna
Green, Simone
Fielding, Adele K.
Falini, Brunangelo
AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (10) : 2018 - 2022
[27] Clinical features of De Novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations
Loghavi, Sanam
Zuo, Zhuang
Ravandi, Farhad
Kantarjian, Hagop M.
Bueso-Ramos, Carlos
Zhang, Liping
Singh, Rajesh R.
Patel, Keyur P.
Medeiros, L. Jeffrey
Stingo, Francesco
Routbort, Mark
Cortes, Jorge
Luthra, Rajyalakshmi
Khoury, Joseph D.
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2014, 7
[28] Simultaneous FLT3, NPM1 and DNMT3A mutations in adult patients with acute myeloid leukemia - case study
Tripon, Florin
Crauciuc, George Andrei
Moldovan, Valeriu George
Boglis, Alina
Benedek, Istvan, Jr.
Lazar, Erzsebet
Banescu, Claudia
REVISTA ROMANA DE MEDICINA DE LABORATOR, 2019, 27 (03): : 245 - 254
[29] Prognostic Impact of Concurrent DNMT3A, FLT3 and NPM1 Gene Mutations in Acute Myeloid Leukemia Patients
Abd Elrhman, Heba Allah E.
El-Meligui, Yomna M.
Elalawi, Saffaa M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (12) : E960 - E969
[30] Prognostic Significance of CEBPA Mutations in a Large Cohort of Younger Adult Patients With Acute Myeloid Leukemia: Impact of Double CEBPA Mutations and the Interaction With FLT3 and NPM1 Mutations
Green, Claire L.
Koo, Kenneth K.
Hills, Robert K.
Burnett, Alan K.
Linch, David C.
Gale, Rosemary E.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (16) : 2739 - 2747

← 1 2 3 4 5 →